Comparative Efficacy of KEYNOTE-B10 Regimen as First-Line (1L) Therapy in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): A Network Meta-Analysis (NMA) with Aggregate-Level Matching

In KEYNOTE-B10, a phase IV, single-arm trial, the combination of pembrolizumab+carboplatin+paclitaxel (referred to as the B10 regimen) demonstrated antitumor activity with a manageable safety profile as 1L therapy for R/M HNSCC. Due to the single-arm design of KEYNOTE-B10, an NMA was conducted using methodologies to incorporate data from a disconnected trial into a connected network of randomized controlled trials (RCT) to estimate the comparative efficacy of the B10 regimen versus other interventions in 1L R/M HNSCC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 141 Source Type: research